The Food and Drug Administration (FDA), United States has approved first vaccine named Dengvaxia for the prevention of dengue disease but with certain conditions that use dengue vaccine only in people who have a previous history of the disease. The vaccine is also known as CYD-TDV and made by company Sanofi Pasteur. The vaccine is a live, attenuated dengue virus. Under the vaccination, 3 doses will be provided to the patient and after 1st dose there will be a difference of 6 months between 1st dose and 2nd dose and also a difference of 6 months between 2nd dose and 3rd dose.
